SKY 1214
Alternative Names: SKY-1214Latest Information Update: 28 Oct 2024
At a glance
- Originator Skyhawk Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Fanconi anaemia complementation group L protein modulators; RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Oct 2024 Pharmacodynamics data from a preclinical studies in Multiple myeloma released by Skyhawk Therapeutics
- 24 Oct 2024 Pharmacodynamics data from a preclinical studies in Non-Hodgkin's lymphoma released by Skyhawk Therapeutics
- 25 Jun 2024 Preclinical trials in Multiple myeloma in USA (PO), prior to July 2024